Chronic obstructive pulmonary disease and bronchiectasis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 2, 2013, Pages 133-139

  Novosad, Shannon A ^a   Barker, Alan F ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

bronchiectasis; COPD; phenotypes; prognosis

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTIFICIAL VENTILATION; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; EMPHYSEMA; GASTROESOPHAGEAL REFLUX; HUMAN; LUNG FUNCTION; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; REVIEW; SPIROMETRY;

BRONCHIECTASIS; HUMANS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84873475082     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835d8312     Document Type: Review

References (61)

1. Kochanek KD, Xu JQ, Murphy SL, et al. Deaths: Preliminary data for 2009. National vital statistics reports. National Center for Health Statistics [Internet]. 2011; 59. Available from http://www.cdc.gov/nchs/data/nvsr/nvsr59/ nvsr 59-04.pdf. Accessed [20 November 2012
2. COPD predicted to be third leading cause of death in 2030 [Internet]. Available from http://www.who.int/gard/news-events/World-Health-Statistics-2008/ en/index.html. [Accessed 20 November 2012
3. Chronic obstructive pulmonary disease (COPD) [Internet]. Available from http://www.who.int/mediacentre/factsheets/fs315/en/index.html. [Accessed 20 November 2012
4. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12:205-209
5. Cole PJ. Inflammation: A two-edged sword - The model of bronchiectasis. Eur J Respir Dis SUPPL1986; 147:6-15
6. Moulton BC, Barker AF. Pathogenesis of bronchiectasis. Clin Chest Med 2012; 33:211-217
7. Tsang KW, Chan K, Ho P, et al. Sputum elastase in steady-State bronchiectasis. Chest 2000; 117:420-426
8. Richman-Eisenstat JB, Jorens PG, Hebert CA, et al. Interleukin-8: An important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993; 264 (4 Pt 1):L413-L418
9. Shum DK, Chan SC, Ip MS. Neutrophil-Mediated degradation of lung proteoglycans: Stimulation by tumor necrosis factor-Alpha in sputum of patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1925-1931
10. Gaga M, Bentley AM, Humbert M, et al. Increases in CD4 T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53:685-691
11. Chan SC, Leung VO, Ip MS, Shum DK. Shed syndecan-1 restricts neutrophil elastase from alpha1-Antitrypsin in neutrophilic airway inflammation. Am J Respir Cell Mol Biol 2009; 41:620-628
12. Stockley RA. Progression of chronic obstructive pulmonary disease: Impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin 2009; 25:1235-1244
13. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012; 122:2749-2755
14. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555
15. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604
16. Celli BR, Cote CG, Marin JM, et al. The body-Mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012
17. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31:869-873
18. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122-135
19. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-1133
20. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931
21. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852
22. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184:662-671
23. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lungvolume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073
24. Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology 2006; 11:731-740
25. Bafadhel M, Umar I, Gupta S, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest 2011; 140:634-642
26. Kinsella M, Muller NL, Abboud RT, et al. Quantitation of emphysema by computed tomography using a 'density mask' program and correlation with pulmonary function tests. Chest 1990; 97:315-321
27. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162 (3 Pt 1):1102-1108
28. Han MK, Bartholmai B, Liu LX, et al. Clinical significance of radiologic characterizations in COPD. COPD 2009; 6:459-467
29. Kim WJ, Hoffman E, Reilly J, et al. Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD. Eur Respir J 2011; 37:39-43
30. Sakao S, Tatsumi K, Igari H, et al. Association of tumor necrosis factor-Alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest 2002; 122:416-420
31. Ito I, Nagai S, Handa T, et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172:1378-1382
32. DeMeo DL, Hersh CP, Hoffman EA, et al. Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med 2007; 176:42-48
33. Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:1309-1315
34. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011; 140:1130-1137
35. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55:635-642
36. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:400-407
37. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006; 35:58-65
38. Engler K, Muhlemann K, Garzoni C, et al. Colonization with Pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients. Swiss Med Wkly 2012; 142:w13509
39. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57:759-764
40. Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med 2003; 97:770-777
41. Marin A, Monso E, Garcia-Nunez M, et al. Variability and effects of bronchial colonization in patients withmoderateCOPD. Eur Respir J 2010; 35:295-302
42. Rosell A, Monso E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:891-897
43. Garcia-Vidal C, Almagro P, Romani V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: A prospective study. Eur Respir J 2009; 34:1072-1078
44. Almagro P, Salvado M, Garcia-Vidal C, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012; 84:36-43
45. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:853-860
46. Parameswaran GI, Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiol 2012; 7:1129-1132
47. Martinez-Solano L, Macia MD, Fajardo A, et al. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008; 47:1526-1533
48. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable noncystic fibrosis bronchiectasis. Chest 2007; 132:1565-1572
49. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: A long-Term study assessing the factors influencing survival. Eur Respir J 2009; 34:843-849
50. Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: The influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9:1601-1604
51. King MA, Stone JA, Diaz PT, et al. Alpha 1-Antitrypsin deficiency: Evaluation of bronchiectasis with CT. Radiology 1996; 199:137-141
52. ShinMS, Ho KJ. Bronchiectasis in patients with alpha 1-Antitrypsin deficiency. A rare occurrence? Chest 1993; 104:1384-1386
53. McMahon MA, O'Mahony MJ, O'Neill SJ, et al. Alpha-1 antitrypsin deficiency and computed tomography findings. J Comput Assist Tomogr 2005; 29:549-553
54. Guest PJ, Hansell DM. High resolution computed tomography (HRCT) in emphysema associated with alpha-1-Antitrypsin deficiency. Clin Radiol 1992; 45:260-266
55. Cuvelier A, Muir JF, Hellot MF, et al. Distribution of alpha(1)-Antitrypsin alleles in patients with bronchiectasis. Chest 2000; 117:415-419
56. Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1-Antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176:1215-1221
57. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7:CD002991
58. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364:1093-1110
59. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-698
60. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 2009; 374:685-694
61. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162 (2 Pt 1):481-485